<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="hwp">aac</journal-id><journal-id journal-id-type="pmc">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7848973</article-id><article-id pub-id-type="pmid">33257443</article-id><article-id pub-id-type="publisher-id">01995-20</article-id><article-id pub-id-type="doi">10.1128/AAC.01995-20</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title><italic>In Vivo</italic> Efficacy and Metabolism of the Antimalarial Cycleanine and Improved <italic>In Vitro</italic> Antiplasmodial Activity of Semisynthetic Analogues</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Uche</surname><given-names>Fidelia Ijeoma</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Xiaozhen</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Okokon</surname><given-names>Jude</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ullah</surname><given-names>Imran</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Horrocks</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Boateng</surname><given-names>Joshua</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huang</surname><given-names>Chenggang</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3706-6068</contrib-id><name><surname>Li</surname><given-names>Wen-Wu</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><aff id="aff1"><label>a</label><addr-line>School of Pharmacy and Bioengineering, Keele University, Stoke-on-Trent, United Kingdom</addr-line></aff><aff id="aff2"><label>b</label><addr-line>Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China</addr-line></aff><aff id="aff3"><label>c</label><addr-line>Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Uyo, Uyo, Nigeria</addr-line></aff><aff id="aff4"><label>d</label><addr-line>School of Medicine, Keele University, Stoke-on-Trent, United Kingdom</addr-line></aff><aff id="aff5"><label>e</label><addr-line>School of Science, University of Greenwich, United Kingdom</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to Chenggang Huang, <email>cghuang@simm.ac.cn</email>, or Wen-Wu Li, <email>w.li@keele.ac.uk</email>.</corresp><fn fn-type="other"><p><bold>Citation</bold> Uche FI, Guo X, Okokon J, Ullah I, Horrocks P, Boateng J, Huang C, Li W-W. 2021. <italic>In vivo</italic> efficacy and metabolism of the antimalarial cycleanine and improved <italic>in vitro</italic> antiplasmodial activity of semisynthetic analogues. Antimicrob Agents Chemother 65:e01995-20. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.01995-20">https://doi.org/10.1128/AAC.01995-20</ext-link>.</p></fn></author-notes><pub-date pub-type="epreprint"><day>30</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>20</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>1</month><year>2021</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>65</volume><issue>2</issue><elocation-id>e01995-20</elocation-id><history><date date-type="received"><day>16</day><month>9</month><year>2020</year></date><date date-type="rev-request"><day>9</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>13</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2021 Uche et al.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Uche et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="AAC.01995-20.pdf"/><abstract abstract-type="precis"><p>Bisbenzylisoquinoline (BBIQ) alkaloids are a diverse group of natural products that demonstrate a range of biological activities. In this study, the <italic>in vitro</italic> antiplasmodial activity of three BBIQ alkaloids (cycleanine [compound 1], isochondodendrine [compound 2], and 2&#x02032;-norcocsuline [compound 3]) isolated from the <named-content content-type="genus-species">Triclisia subcordata</named-content> Oliv. medicinal plant traditionally used for the treatment of malaria in Nigeria are studied alongside two semisynthetic analogues (compounds 4 and 5) of cycleanine.</p></abstract><abstract><title>ABSTRACT</title><p>Bisbenzylisoquinoline (BBIQ) alkaloids are a diverse group of natural products that demonstrate a range of biological activities. In this study, the <italic>in vitro</italic> antiplasmodial activity of three BBIQ alkaloids (cycleanine [compound 1], isochondodendrine [compound 2], and 2&#x02032;-norcocsuline [compound 3]) isolated from the <named-content content-type="genus-species">Triclisia subcordata</named-content> Oliv. medicinal plant traditionally used for the treatment of malaria in Nigeria are studied alongside two semisynthetic analogues (compounds 4 and 5) of cycleanine. The antiproliferative effects against a chloroquine-resistant <named-content content-type="genus-species">Plasmodium falciparum</named-content> strain were determined using a SYBR green 1 fluorescence assay. The <italic>in vivo</italic> antimalarial activity of cycleanine is then investigated in suppressive, prophylactic, and curative murine malaria models after infection with a chloroquine-sensitive <named-content content-type="genus-species">Plasmodium berghei</named-content> strain. BBIQ alkaloids (compounds 1 to 5) exerted <italic>in vitro</italic> antiplasmodial activities with 50% inhibitory concentration (IC<sub>50</sub>) at low micromolar concentrations and the two semisynthetic cycleanine analogues showed an improved potency and selectivity compared to those of cycleanine. At oral doses of 25 and 50&#x02009;mg/kg body weight of infected mice, cycleanine suppressed the levels of parasitemia and increased mean survival times significantly compared to those of the control groups. The metabolites and metabolic pathways of cycleanine were also studied using high-performance liquid chromatography&#x02013;electrospray ionization&#x02013;tandem mass spectrometry. Twelve novel metabolites were detected in rats after intragastric administration of cycleanine. The metabolic pathways of cycleanine were demonstrated to involve hydroxylation, dehydrogenation, and demethylation. Overall, these <italic>in vitro</italic> and <italic>in vivo</italic> results provide a basis for the future evaluation of cycleanine and its analogues as leads for further development.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>malaria</kwd><kwd><italic>Plasmodium falciparum</italic></kwd><kwd><italic>Plasmodium berghei</italic></kwd><kwd>bisbenzylisoquinoline alkaloids</kwd><kwd>cycleanine</kwd><kwd>metabolism</kwd><kwd><italic>in vivo</italic> activity</kwd><kwd>antimalarial agents</kwd><kwd>drug metabolism</kwd></kwd-group><counts><fig-count count="3"/><table-count count="4"/><equation-count count="1"/><ref-count count="44"/><page-count count="11"/><word-count count="6837"/></counts><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>TEXT</title><p>In 2018, the World Health Organization (WHO) report estimated a global burden of 228 million cases accounting for 405,000 deaths (<xref rid="B1" ref-type="bibr">1</xref>). The majority of this burden fell on the WHO Africa Region, where malaria, particularly that caused by the most virulent etiological agent <named-content content-type="genus-species">Plasmodium falciparum</named-content>, exerts an immense economic impact. While malaria cases and mortality figures continue to fall (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>), the development and spread of resistance to available chemotherapeutic agents poses a significant threat to malaria treatment and management (<xref rid="B3" ref-type="bibr">3</xref>). Natural products of plant origin have traditionally provided good sources for discovery of drug leads or novel compounds in modern drug research (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). For example, artemisinin isolated from <named-content content-type="genus-species">Artemisia annua</named-content>, sweet wormwood, a traditional Chinese medicine, together with a series of its semisynthetic derivatives, has become the first-line therapy for <named-content content-type="genus-species">P. falciparum</named-content> malaria (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). However, due to the development of artemisinin drug resistance (<xref rid="B8" ref-type="bibr">8</xref>), novel therapies are still urgently needed.</p><p>Bisbenzylisoquinoline (BBIQ) alkaloids are a diverse group of natural products consisting of two benzylisoquinoline groups (<xref rid="B9" ref-type="bibr">9</xref>). BBIQ alkaloids are primarily found in the <named-content content-type="genus-species">Berberidaceae</named-content>, <named-content content-type="genus-species">Lauraceae</named-content>, <named-content content-type="genus-species">Menispermaceae</named-content>, and <named-content content-type="genus-species">Ranunculaceae</named-content> plant families. These alkaloids possess a variety of biological activities, which include antimalarial activities (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). For example, BBIQ alkaloids isolated and identified from <named-content content-type="genus-species">Triclisia</named-content> species of the <italic>Menispermaceae</italic> family have antiproliferative activities (<xref rid="B10" ref-type="bibr">10</xref>). In Nigeria, the root of <named-content content-type="genus-species">Triclisia subcordata</named-content> Oliv. is traditionally used for the treatment of a range of diseases, including malaria (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). The bioactive components of <named-content content-type="genus-species">T. subcordata</named-content> are the BBIQ alkaloids cycleanine (compound 1), isochondodendrine (compound 2) and 2&#x02032;-norcocsuline (compound 3) (<xref ref-type="fig" rid="F1">Fig. 1</xref>) and have previously been isolated and characterized by our group (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). We have also produced synthetic analogues of cycleanine (compounds 4 and 5) (<xref ref-type="fig" rid="F1">Fig. 1</xref>) (<xref rid="B15" ref-type="bibr">15</xref>). The three naturally occurring BBIQ alkaloids, cycleanine (<xref rid="B16" ref-type="bibr">16</xref><xref ref-type="bibr" rid="B17">&#x02013;</xref><xref rid="B18" ref-type="bibr">18</xref>), isochondodendrine (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>), and 2&#x02032;-norcocsuline (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B20" ref-type="bibr">20</xref>) have been reported to possess antiplasmodial effects against chloroquine-sensitive and chloroquine-resistant <named-content content-type="genus-species">P. falciparum</named-content> strains. Despite the promising <italic>in vitro</italic> biological activity of these natural BBIQ alkaloids, the <italic>in vivo</italic> antimalarial activity of BBIQ alkaloids has not been evaluated, nor has their potential <italic>in vivo</italic> metabolism. Here, we assess the <italic>in vivo</italic> antimalarial activity and metabolism of cycleanine (compound 1). The effect of cycleanine analogues (compounds 4 and 5) on antiplasmodial potency and selectivity is also investigated.</p><fig id="F1" orientation="portrait" position="float"><label>FIG 1</label><caption><p>Chemical structure of bisbenzylisoquinoline (BBIQ) alkaloids. Cycleanine (compound 1), isochondodendrine (compound 2), and 2&#x02032;-norcocsuline (compound 3) from <named-content content-type="genus-species">T. subcordata</named-content> and two novel semisynthetic analogues (compounds 4 and 5) of cycleanine.</p></caption><graphic xlink:href="AAC.01995-20-f0001"/></fig><p>This study sets out an evaluation of the <italic>in vitro</italic> antimalarial activities of BBIQ alkaloid compounds 1 to 3 compared to those of two semisynthetic BBIQ alkaloids (compounds 4 and 5) derived by a modification of cycleanine at the C-5 position by introducing additional secondary or tertiary amine moieties in an attempt to increase potential solubility and potency (<xref rid="B15" ref-type="bibr">15</xref>). The most abundant BBIQ alkaloid in <italic>T. subcordata</italic> extract is cycleanine; this was therefore used to establish <italic>in vivo</italic> antimalarial activity in a murine malaria model. In addition, the metabolites and metabolic pathways of cycleanine were analyzed after intragastric administration in rats to help understand how cycleanine is eliminated <italic>in vivo</italic> to guide future optimization of cycleanine for antimalarial development.</p></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2.1"><title>The semisynthetic derivatives of cycleanine have improved <italic>in vitro</italic> antiplasmodial activity and selectivity.</title><p>The <italic>in vitro</italic> antiplasmodial activities of the five BBIQ alkaloids (compounds 1 to 5), as well as that of a chloroquine control, were determined against intraerythrocytic stages of the <named-content content-type="genus-species">P. falciparum</named-content> Dd2 chloroquine-resistant strain using a malaria SYBR green I fluorescence assay. These data are provided in <xref rid="T1" ref-type="table">Table 1</xref> (see Fig. S1 in the supplemental material) as 50% inhibitory concentration (IC<sub>50</sub>) values (mean &#x000b1; standard deviation [SD] for <italic>n</italic>&#x02009;=&#x02009;3 independent biological repeats). While the data for chloroquine in Dd2 are comparable to those of the chloroquine-resistant strain W2, the activities of cycleanine, isochondodendrine, and 2&#x02032;-norcocsuline are significantly lower in Dd2 than that reported in W2, and certainly lower than that in the chloroquine-sensitive strain D6. The semisynthetic products 4 and 5 are relatively more potent than compound 1 to 3 in Dd2, with the most potent, compound 4, being some 25.2-fold more potent than its natural precursor, cycleanine (compound 1).</p><table-wrap id="T1" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Cytotoxicity data for BBIQ alkaloids</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">BBIQ alkaloid (compound no.)</th><th colspan="3" rowspan="1">IC<sub>50</sub> (&#x003bc;M) against <named-content content-type="genus-species">P. falciparum</named-content> strain<xref ref-type="table-fn" rid="T1F1"><sup><italic>a</italic></sup></xref><sup>,</sup><xref ref-type="table-fn" rid="T1F4"><sup><italic>d</italic></sup></xref>:<hr/></th><th colspan="2" rowspan="1">CC<sub>50</sub> (&#x003bc;M) against cancer cell line(s):<hr/></th><th colspan="2" rowspan="1">SI<xref ref-type="table-fn" rid="T1F6"><sup><italic>f</italic></sup></xref><hr/></th></tr><tr><th rowspan="1" colspan="1">Dd2</th><th rowspan="1" colspan="1">W2</th><th rowspan="1" colspan="1">D6</th><th rowspan="1" colspan="1">KB<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref> or HCT<xref ref-type="table-fn" rid="T1F3"><sup><italic>c</italic></sup></xref></th><th rowspan="1" colspan="1">HOE<xref ref-type="table-fn" rid="T1F5"><sup><italic>e</italic></sup></xref></th><th rowspan="1" colspan="1">KB/W2</th><th rowspan="1" colspan="1">HOE/Dd2</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cycleanine (1)</td><td rowspan="1" colspan="1">17.7&#x02009;&#x000b1;&#x02009;2.0</td><td rowspan="1" colspan="1">0.25<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref>; 4.5<xref ref-type="table-fn" rid="T1F3"><sup><italic>c</italic></sup></xref></td><td rowspan="1" colspan="1">0.07<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">&#x0003e;33.7<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref>; 531 (HCT)<xref ref-type="table-fn" rid="T1F3"><sup><italic>c</italic></sup></xref></td><td rowspan="1" colspan="1">35.0&#x02009;&#x000b1;&#x02009;0.1</td><td rowspan="1" colspan="1">&#x0003e;133</td><td rowspan="1" colspan="1">2.0</td></tr><tr><td rowspan="1" colspan="1">Isochondodendrine (2)</td><td rowspan="1" colspan="1">6.1&#x02009;&#x000b1;&#x02009;1.3</td><td rowspan="1" colspan="1">0.2<xref ref-type="table-fn" rid="T1F3"><sup><italic>c</italic></sup></xref></td><td rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="T1F4"><sup><italic>d</italic></sup></xref></td><td rowspan="1" colspan="1">29 (HCT)<xref ref-type="table-fn" rid="T1F3"><sup><italic>c</italic></sup></xref></td><td rowspan="1" colspan="1">10.5&#x02009;&#x000b1;&#x02009;1.2</td><td rowspan="1" colspan="1">116</td><td rowspan="1" colspan="1">1.7</td></tr><tr><td rowspan="1" colspan="1">2&#x02032;-Norcocsuline (3)</td><td rowspan="1" colspan="1">7.0&#x02009;&#x000b1;&#x02009;1.6</td><td rowspan="1" colspan="1">0.28<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">0.048<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">3.8<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">8.0&#x02009;&#x000b1;&#x02009;0.2</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">1.1</td></tr><tr><td rowspan="1" colspan="1">5-[(Dimethylamino)methyl]cycleanine (4)</td><td rowspan="1" colspan="1">0.7&#x02009;&#x000b1;&#x02009;0.1</td><td rowspan="1" colspan="1">ND</td><td rowspan="1" colspan="1">ND</td><td rowspan="1" colspan="1">ND</td><td rowspan="1" colspan="1">10.0&#x02009;&#x000b1;&#x02009;0.2</td><td rowspan="1" colspan="1">ND</td><td rowspan="1" colspan="1">14.3</td></tr><tr><td rowspan="1" colspan="1">5-[(Propargylamino)methyl]cycleanine (5)</td><td rowspan="1" colspan="1">1.8&#x02009;&#x000b1;&#x02009;0.2</td><td rowspan="1" colspan="1">ND</td><td rowspan="1" colspan="1">ND</td><td rowspan="1" colspan="1">ND</td><td rowspan="1" colspan="1">32.0&#x02009;&#x000b1;&#x02009;1.6</td><td rowspan="1" colspan="1">ND</td><td rowspan="1" colspan="1">17.8</td></tr><tr><td rowspan="1" colspan="1">Chloroquine</td><td rowspan="1" colspan="1">0.18&#x02009;&#x000b1;&#x02009;0.03</td><td rowspan="1" colspan="1">0.135<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">0.006<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">33.7<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">ND</td><td rowspan="1" colspan="1">250</td><td rowspan="1" colspan="1">ND</td></tr></tbody></table><graphic xlink:href="AAC.01995-20-t0001"/></alternatives><table-wrap-foot><fn fn-type="other" id="T1F1"><label>a</label><p><italic>In vitro</italic> 50% inhibitory concentration (IC<sub>50</sub>) values of BBIQ alkaloids (compounds 1 to 5) against <named-content content-type="genus-species">P. falciparum</named-content> chloroquine-resistant strains (Dd2 and W2 strains) and the chloroquine-sensitive strain (D6). IC<sub>50</sub> values are expressed as mean &#x000b1; SD for <italic>n</italic>&#x02009;=&#x02009;3 independent biological repeats.</p></fn><fn fn-type="other" id="T1F2"><label>b</label><p>IC<sub>50</sub> data against <named-content content-type="genus-species">P. falciparum</named-content> W2 and D6 strains and 50% cytotoxic concentration (CC<sub>50</sub>) values for human oral epidermoid carcinoma (KB) cells were sourced from a previous report (<xref rid="B16" ref-type="bibr">16</xref>).</p></fn><fn fn-type="other" id="T1F3"><label>c</label><p>IC<sub>50</sub> data against chloroquine-resistant <named-content content-type="genus-species">P. falciparum</named-content> strain W2 and CC<sub>50</sub> values for HCT-116 human colon carcinoma cells were sourced from a previous report (<xref rid="B18" ref-type="bibr">18</xref>).</p></fn><fn fn-type="abbr" id="T1F4"><label>d</label><p>ND, not determined.</p></fn><fn fn-type="other" id="T1F5"><label>e</label><p>CC<sub>50</sub> data for human ovarian epithelial (HOE) cells. Data in this column for compounds 1 to 5 were sourced from our previous reports (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B15" ref-type="bibr">15</xref>).</p></fn><fn fn-type="other" id="T1F6"><label>f</label><p>This selectivity index (SI) was calculated as CC<sub>50</sub> /IC<sub>50</sub> against <named-content content-type="genus-species">P. falciparum</named-content>.</p></fn></table-wrap-foot></table-wrap><p>Data from cytotoxicity studies of BBIQ alkaloids 1 to 3 in human oral epidermoid carcinoma (KB) or HCT-116 human colon carcinoma cells suggest low to moderate selectivity, with a selectivity index (SI) of 14 to &#x0003e;133. Fifty percent cytotoxic concentration (CC<sub>50</sub>) data for all five compounds are available from human ovarian epithelial (HOE) cells (<xref rid="T1" ref-type="table">Table 1</xref>). These data reinforce the findings of low selectivity, albeit improved in semisynthetic products 4 and 5.</p></sec><sec id="s2.2"><title><italic>In vivo</italic> antimalarial activity of cycleanine (compound 1).</title><p>The isolation of the abundant cycleanine (compound 1) in <italic>T. subcordata</italic> root enabled us to investigate its toxicity in healthy mice and efficacy in murine malaria models after infection with <named-content content-type="genus-species">Plasmodium berghei</named-content>. The acute median lethal dose (LD<sub>50</sub>) of cycleanine after 24-h oral administration was determined to be 4.5 g/kg in mice, indicating a good safety profile. The malaria-suppressive activity of cycleanine using two oral doses (25 and 50&#x02009;mg/kg of body weight/day) following <named-content content-type="genus-species">P. berghei</named-content> infection was demonstrated through a significant suppression of parasitemia and an increased mean survival time (MST) compared to those of untreated controls (<xref rid="T2" ref-type="table">Table 2</xref>). In particular, the higher dose (50&#x02009;mg/kg/day) showed efficacy, both in terms of suppression of parasitemia and in MST, comparable to that for chloroquine at a dose of 5&#x02009;mg/kg/day. The prophylactic activity of cycleanine, with the same 25 and 50&#x02009;mg/kg dosing regimen during <named-content content-type="genus-species">P. berghei</named-content> infection in mice, was also demonstrated (<xref rid="T3" ref-type="table">Table 3</xref>). At the higher dose (50&#x02009;mg/kg), cycleanine showed a suppression of parasitemia by 59.0%, only slightly less than that of 76.2% using the prophylactic pyrimethamine control at a dose of 1.2&#x02009;mg/kg /day.</p><table-wrap id="T2" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>Suppressive activity of cycleanine during early <named-content content-type="genus-species">Plasmodium berghei</named-content> infection of mice</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Treatment</th><th rowspan="1" colspan="1">Dose (mg/kg) per day</th><th rowspan="1" colspan="1">Parasitemia after infection for 96 h (%)<xref ref-type="table-fn" rid="T2F1"><sup><italic>a</italic></sup></xref></th><th rowspan="1" colspan="1">Suppression of parasitemia at 96 h (%)<xref ref-type="table-fn" rid="T2F1"><sup><italic>a</italic></sup></xref></th><th rowspan="1" colspan="1">MST (days)<xref ref-type="table-fn" rid="T2F1"><sup><italic>a</italic></sup></xref></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Untreated control</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">28.3&#x02009;&#x000b1;&#x02009;1.8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">12.5&#x02009;&#x000b1;&#x02009;0.3</td></tr><tr><td rowspan="2" colspan="1">Cycleanine</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">15.7&#x02009;&#x000b1;&#x02009;1.8<xref ref-type="table-fn" rid="T2F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">44.7</td><td rowspan="1" colspan="1">24.7&#x02009;&#x000b1;&#x02009;1.1<xref ref-type="table-fn" rid="T2F2"><sup><italic>b</italic></sup></xref></td></tr><tr><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">3.8&#x02009;&#x000b1;&#x02009;0.7<xref ref-type="table-fn" rid="T2F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">86.5</td><td rowspan="1" colspan="1">28.2&#x02009;&#x000b1;&#x02009;0.9<xref ref-type="table-fn" rid="T2F2"><sup><italic>b</italic></sup></xref></td></tr><tr><td rowspan="1" colspan="1">Chloroquine</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">2.0&#x02009;&#x000b1;&#x02009;0.8<xref ref-type="table-fn" rid="T2F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">94.0</td><td rowspan="1" colspan="1">30.0&#x02009;&#x000b1;&#x02009;0.0<xref ref-type="table-fn" rid="T2F2"><sup><italic>b</italic></sup></xref></td></tr></tbody></table><graphic xlink:href="AAC.01995-20-t0002"/></alternatives><table-wrap-foot><fn fn-type="other" id="T2F1"><label>a</label><p>Values are expressed as mean &#x000b1; standard error of the mean (SEM) (<italic>n</italic>&#x02009;=&#x02009;6 in each group).</p></fn><fn fn-type="other" id="T2F2"><label>b</label><p>Significant relative to untreated control; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>TABLE 3</label><caption><p>Prophylactic activity of cycleanine in <named-content content-type="genus-species">Plasmodium berghei</named-content> infection of mice</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Treatment</th><th rowspan="1" colspan="1">Dose (mg/kg) per day</th><th rowspan="1" colspan="1">Parasitemia level after infection for 72 h (%)<xref ref-type="table-fn" rid="T3F1"><sup><italic>a</italic></sup></xref></th><th rowspan="1" colspan="1">Suppression of parasitemia level after infection for 72 h (%)<xref ref-type="table-fn" rid="T3F1"><sup><italic>a</italic></sup></xref></th><th rowspan="1" colspan="1">MST (days)<xref ref-type="table-fn" rid="T3F1"><sup><italic>a</italic></sup></xref></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Untreated control</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">20.3&#x02009;&#x000b1;&#x02009;0.8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">12.7&#x02009;&#x000b1;&#x02009;0.3</td></tr><tr><td rowspan="2" colspan="1">Cycleanine</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">11.5&#x02009;&#x000b1;&#x02009;0.9<xref ref-type="table-fn" rid="T3F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">43.4</td><td rowspan="1" colspan="1">23.0&#x02009;&#x000b1;&#x02009;0.6<xref ref-type="table-fn" rid="T3F2"><sup><italic>b</italic></sup></xref></td></tr><tr><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">8.3&#x02009;&#x000b1;&#x02009;1.0<xref ref-type="table-fn" rid="T3F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">59.0</td><td rowspan="1" colspan="1">24.5&#x02009;&#x000b1;&#x02009;0.6<xref ref-type="table-fn" rid="T3F2"><sup><italic>b</italic></sup></xref></td></tr><tr><td rowspan="1" colspan="1">Pyrimethamine</td><td rowspan="1" colspan="1">1.2</td><td rowspan="1" colspan="1">4.8&#x02009;&#x000b1;&#x02009;1.1<xref ref-type="table-fn" rid="T3F2"><sup><italic>b</italic></sup></xref></td><td rowspan="1" colspan="1">76.2</td><td rowspan="1" colspan="1">29.8&#x02009;&#x000b1;&#x02009;0.2<xref ref-type="table-fn" rid="T3F2"><sup><italic>b</italic></sup></xref></td></tr></tbody></table><graphic xlink:href="AAC.01995-20-t0003"/></alternatives><table-wrap-foot><fn fn-type="other" id="T3F1"><label>a</label><p>Values are expressed as mean &#x000b1; SEM (<italic>n</italic>&#x02009;=&#x02009;6 in each group).</p></fn><fn fn-type="other" id="T3F2"><label>b</label><p>Significant relative to control; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></fn></table-wrap-foot></table-wrap><p>The curative activity and MST of mice after initial <named-content content-type="genus-species">P. berghei</named-content> infection and subsequent treatment with cycleanine (compound 1) were determined. After infection of mice for 3 days, cycleanine was administered at both doses of 25 and 50&#x02009;mg/kg and mice showed decreasing parasitemia in a dose-dependent and time-dependent manner from day 3 to day 7 (<xref ref-type="fig" rid="F2">Fig. 2</xref>). The speed of killing of <named-content content-type="genus-species">P. berghei</named-content> parasites by chloroquine was much faster than that with cycleanine. Chloroquine reached 0% parasitemia after 5&#x02009;days, while at that time cycleanine at doses of 25 and 50&#x02009;mg/kg had remaining levels of 13.3 and 10.5%, respectively (<xref ref-type="fig" rid="F2">Fig. 2</xref>). In this curative model, the MST of mice at doses of 25 and 50&#x02009;mg/kg were 21 and 25&#x02009;days, respectively, which were significantly longer than that of the control (12&#x02009;days). However, they were both shorter than that of mice treated with chloroquine (30&#x02009;days) (see Table S1 in the supplemental material).</p><fig id="F2" orientation="portrait" position="float"><label>FIG 2</label><caption><p>The curative activity of mice treated with cycleanine (compound 1) during established <named-content content-type="genus-species">P. berghei</named-content> infection. After infection of mice for 3&#x02009;days, cycleanine was administered at both doses of 25 and 50&#x02009;mg/kg, while water and chloroquine at 5&#x02009;mg/ml were administered as negative and positive controls, respectively. The parasitemia levels were monitored for a total duration of 4&#x02009;days (from day 3 to day 7).</p></caption><graphic xlink:href="AAC.01995-20-f0002"/></fig></sec><sec id="s2.3"><title><italic>In vivo</italic> metabolism of cycleanine.</title><p>In order to explore the <italic>in vivo</italic> metabolism of cycleanine, the plasma and urine of Wistar rats following an oral dose of 120&#x02009;mg/kg body weight/day over a 24-h period were analyzed for cycleanine metabolites. Samples from urine and plasma were prepared and submitted to high-performance liquid chromatography&#x02013;electrospray ionization&#x02013;tandem mass spectrometry (HPLC-ESI-MS/MS) analysis. The peak at the retention time of 9.7&#x02009;min was cycleanine (M0) with the protonated molecular ion <italic>m/z</italic> of 623.3116 [M+H]<sup>+</sup> (elemental composition C<sub>18</sub>H<sub>43</sub>N<sub>2</sub>O<sub>6</sub>) in the positive ion mode spectrum (<xref rid="T4" ref-type="table">Table 4</xref> and <xref ref-type="fig" rid="F3">Fig. 3</xref>; see also Fig. S2 in the supplemental material). In MS/MS, the quasimolecular ion loses a neutral molecular NH<sub>2</sub>CH<sub>3</sub> fragment to generate an ion <italic>m/z</italic> of 592.2694 also by symmetric cleavage, and breaking C-O and C-C bonds to produce a fragment ion <italic>m/z</italic> of 312.1594, which can also lose C<sub>2</sub>H<sub>6</sub> to produce a fragment ion <italic>m/z</italic> of 282.1125. After another C-O and C-C bond cleavage and the subsequent loss of CH<sub>3</sub> and OCH<sub>3</sub>, fragment ions <italic>m/z</italic> 204.101, 190.0863, and 159.0679 were generated. A fragment ion <italic>m/z</italic> of 400.1907 was also generated by simultaneous C-O bond cleavage and C-C bond cleavage adjacent to the N atom (<xref ref-type="fig" rid="F3">Fig. 3</xref> and Fig. S2).</p><fig id="F3" orientation="portrait" position="float"><label>FIG 3</label><caption><p>Possible fragmentation pattern of cycleanine. For analysis of fragment ions, see the text.</p></caption><graphic xlink:href="AAC.01995-20-f0003"/></fig><table-wrap id="T4" orientation="portrait" position="float"><label>TABLE 4</label><caption><p>HPLC-QTOF-MS retention times and mass spectrometric data of cycleanine and its metabolites</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Prototype or metabolite</th><th rowspan="1" colspan="1"><italic>t</italic> (min)</th><th rowspan="1" colspan="1">Measured [M+H]<sup>+</sup>
<italic>m/z</italic></th><th rowspan="1" colspan="1">&#x00394;ppm</th><th rowspan="1" colspan="1">Formula</th><th rowspan="1" colspan="1">MS/MS fragment(s)</th><th rowspan="1" colspan="1">Metabolic pathway(s)</th><th rowspan="1" colspan="1">Plasma</th><th rowspan="1" colspan="1">Urine</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">M0</td><td rowspan="1" colspan="1">9.9</td><td rowspan="1" colspan="1">623.3125</td><td rowspan="1" colspan="1">1.41</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>43</sub>N<sub>2</sub>O<sub>6</sub></td><td rowspan="1" colspan="1">592.2696, 400.1895, 312.1583, 311.1508, 281.1165, 204.1011, 190.0857, 174.0911, 159.1038</td><td rowspan="1" colspan="1">Parent</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M1</td><td rowspan="1" colspan="1">7.2</td><td rowspan="1" colspan="1">639.3075</td><td rowspan="1" colspan="1">1.36</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>43</sub>N<sub>2</sub>O<sub>7</sub></td><td rowspan="1" colspan="1">592.2472, 416.1838, 310.1422, 220.0964, 204.1046, 190.0815, 175.0955, 157.0901</td><td rowspan="1" colspan="1">Hydroxylation</td><td rowspan="1" colspan="1">&#x02212;</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M2</td><td rowspan="1" colspan="1">7.9</td><td rowspan="1" colspan="1">639.3084</td><td rowspan="1" colspan="1">2.79</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>43</sub>N<sub>2</sub>O<sub>7</sub></td><td rowspan="1" colspan="1">621.2977, 416.1864, 400.1917, 327.1469, 312.1361, 220.0964, 206.0780, 175.0988</td><td rowspan="1" colspan="1">Hydroxylation</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M3</td><td rowspan="1" colspan="1">8.1</td><td rowspan="1" colspan="1">625.2911</td><td rowspan="1" colspan="1">0.84</td><td rowspan="1" colspan="1">C<sub>37</sub>H<sub>41</sub>N<sub>2</sub>O<sub>7</sub></td><td rowspan="1" colspan="1">607.2784, 425.1379, 312.1591, 298.1434, 204.0999, 190.0854, 176.0691, 159.1033</td><td rowspan="1" colspan="1">Demethylation and hydroxylation</td><td rowspan="1" colspan="1">&#x02212;</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M4</td><td rowspan="1" colspan="1">9.6</td><td rowspan="1" colspan="1">609.2956</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">C<sub>37</sub>H<sub>41</sub>N<sub>2</sub>O<sub>6</sub></td><td rowspan="1" colspan="1">593.2750, 427.1577, 357.1449, 312.1580, 298.1435, 204.1020, 190.0850, 176.0704, 145.0880</td><td rowspan="1" colspan="1">Demethylation</td><td rowspan="1" colspan="1">&#x02212;</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M5</td><td rowspan="1" colspan="1">10.1</td><td rowspan="1" colspan="1">595.2799</td><td rowspan="1" colspan="1">0.73</td><td rowspan="1" colspan="1">C<sub>36</sub>H<sub>39</sub>N<sub>2</sub>O<sub>6</sub></td><td rowspan="1" colspan="1">578.2505, 284.1282, 176.0703, 145.0879</td><td rowspan="1" colspan="1">Didemethylation</td><td rowspan="1" colspan="1">&#x02212;</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M6</td><td rowspan="1" colspan="1">10.4</td><td rowspan="1" colspan="1">637.2918</td><td rowspan="1" colspan="1">1.12</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>41</sub>N<sub>2</sub>O<sub>7</sub></td><td rowspan="1" colspan="1">328.1553, 309.1381, 202.0855, 188.0656, 157.0879</td><td rowspan="1" colspan="1">Dehydrogenation and hydroxylation</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M7</td><td rowspan="1" colspan="1">11.1</td><td rowspan="1" colspan="1">653.2855</td><td rowspan="1" colspan="1">0.38</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>41</sub>N<sub>2</sub>O<sub>8</sub></td><td rowspan="1" colspan="1">635.2754, 326.1384, 309.1381, 202.0855, 188.0656, 157.0879</td><td rowspan="1" colspan="1">Dehydrogenation and dihydroxylation</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02212;</td></tr><tr><td rowspan="1" colspan="1">M8</td><td rowspan="1" colspan="1">12.1</td><td rowspan="1" colspan="1">653.2868</td><td rowspan="1" colspan="1">1.23</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>41</sub>N<sub>2</sub>O<sub>8</sub></td><td rowspan="1" colspan="1">592.2459, 310.1420, 293.1154, 281.1163, 269.1169, 204.1031, 190.0884</td><td rowspan="1" colspan="1">Dehydrogenation and dihydroxylation</td><td rowspan="1" colspan="1">&#x02212;</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M9</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">653.2856</td><td rowspan="1" colspan="1">0.27</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>41</sub>N<sub>2</sub>O<sub>8</sub></td><td rowspan="1" colspan="1">635.2701, 400.1881, 326.1380, 310.1427, 202.0855, 173.0820, 157.0881</td><td rowspan="1" colspan="1">Dehydrogenation and dihydroxylation</td><td rowspan="1" colspan="1">&#x02212;</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M10</td><td rowspan="1" colspan="1">13.4</td><td rowspan="1" colspan="1">621.2966</td><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>41</sub>N<sub>2</sub>O<sub>6</sub></td><td rowspan="1" colspan="1">591.2467, 400.1893, 398.1739, 312.1572, 310.1435, 204.1013, 202.0860, 190.0863, 188.0725, 159.1028, 157.0883</td><td rowspan="1" colspan="1">Dehydrogenation</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02212;</td></tr><tr><td rowspan="1" colspan="1">M11</td><td rowspan="1" colspan="1">13.6</td><td rowspan="1" colspan="1">653.2859</td><td rowspan="1" colspan="1">0.73</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>41</sub>N<sub>2</sub>O<sub>8</sub></td><td rowspan="1" colspan="1">413.1375, 324.1595, 309.1345, 281.1158, 204.1015, 159.1021</td><td rowspan="1" colspan="1">Dehydrogenation and dihydroxylation</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">M12</td><td rowspan="1" colspan="1">14.1</td><td rowspan="1" colspan="1">637.2919</td><td rowspan="1" colspan="1">1.61</td><td rowspan="1" colspan="1">C<sub>38</sub>H<sub>41</sub>N<sub>2</sub>O<sub>7</sub></td><td rowspan="1" colspan="1">594.2486, 414.1684, 326.1381, 312.1237, 281.1159, 218.0824, 204.1013, 190.0874, 173.0830</td><td rowspan="1" colspan="1">Dehydrogenation and hydroxylation</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr></tbody></table><graphic xlink:href="AAC.01995-20-t0004"/></alternatives></table-wrap><p>Twelve peaks on LC-MS/MS chromatograms relevant to cycleanine were detected in either urine or plasma samples (<xref rid="T4" ref-type="table">Table 4</xref> and Fig. S3 in the supplemental material). The original form of cycleanine and 11 metabolites were found from the urine of rats, which were presumed to be hydroxylation (M1 and M2), demethylation and hydroxylation (M3), monodemethylation (M4), didemethylation (M5), dehydrogenation and hydroxylation (M6 and M12), and dehydrogenation and dihydroxylation (M7) metabolites, and the isomeric metabolites of M7 (M8, M9, and M11). From the cycleanine-containing plasma of rats, the original form cycleanine (M0) and five metabolites were found, which were presumed to be hydroxylation (M2 and M10), dehydrogenation and hydroxylation (M6 and M12), and dehydrogenation and dihydroxylation (M7) metabolites. Among them, the prototype (M0), hydroxylation (M1), and dehydrogenation and hydroxylation (M6, M12) metabolites were detected in both rat urine and plasma (<xref rid="T4" ref-type="table">Table 4</xref> and supplemental material). Therefore, the metabolic pathway of cycleanine in rats involves hydroxylation, dehydrogenation, and demethylation or their combination, which are the main means of biotransformation of cycleanine to generate a large number of metabolites (M1 to M12) (see Fig. S5 in the supplemental material).</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>Natural products (e.g., artemisinin and quinine) have demonstrated their potential as a source of antimalarial drugs. Previously, a number of BBIQ alkaloids were demonstrated to have <italic>in vitro</italic> antiplasmodial activities (<xref rid="B16" ref-type="bibr">16</xref>). Cycleanine had antiplasmodial effects with an IC<sub>50</sub> of 70&#x02009;nM (<xref rid="B16" ref-type="bibr">16</xref>) (or 80&#x02009;nM [<xref rid="B17" ref-type="bibr">17</xref>]) against <named-content content-type="genus-species">P. falciparum</named-content> chloroquine-sensitive clone D6 (or 3D7) and an IC<sub>50</sub> of 4.5&#x02009;&#x003bc;M against a chloroquine-resistant strain (<xref rid="B18" ref-type="bibr">18</xref>). Isochondodendrine showed a low IC<sub>50</sub> of 0.2&#x02009;&#x003bc;M against a chloroquine-resistant strain (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). 2&#x02032;-Norcocsuline also showed potent <italic>in vitro</italic> antiplasmodial activity, with IC<sub>50</sub> values of 48 and 248&#x02009;nM against chloroquine-sensitive clone D6 (3D7) and chloroquine-resistant clone W2 (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B20" ref-type="bibr">20</xref>), respectively (<xref rid="T1" ref-type="table">Table 1</xref>). Our results against <named-content content-type="genus-species">P. falciparum</named-content> chloroquine-resistant strain Dd2 also confirmed the <italic>in vitro</italic> antimalarial activity of these compounds but with slightly higher IC<sub>50</sub> values (<xref rid="T1" ref-type="table">Table 1</xref>) compared to the corresponding values reported in literature. Isochododendrine is a structurally demethylated analogue of cycleanine, and showed a greater potency than cycleanine in the chloroquine-resistant W2 strain and the Dd2 strain in this study (<xref rid="T1" ref-type="table">Table 1</xref>). This indicated that the increase of the hydrophilicity of cycleanine could improve its antiplasmodial activity. The SI values of all three BBIQ alkaloids ranged from 14 to 133 based on the KB or HTC-116 cells and the W2 strain, which were much greater than those based on HOE cells and the Dd2 strain. The discrepancy might be due to the different methodologies (<xref rid="B16" ref-type="bibr">16</xref>) used to determine IC<sub>50</sub> or the different mammalian cancer cells or <named-content content-type="genus-species">P. falciparum</named-content> clones used. The semisynthetic analogues of cycleanine (compounds 4 and 5) produced by chemical modification of cycleanine through introduction of dimethylamino and (mono)alkynylamino groups, respectively, at the C-5 position exhibited increase in antiplasmodial potency and SI relative to cycleanine. The presence of a dimethylamino group in compound 4 could also increase the water solubility of the parent compound as is often found in the modification of other natural products, such as camptothecin (<xref rid="B21" ref-type="bibr">21</xref>) and thymoquinone (<xref rid="B22" ref-type="bibr">22</xref>). Compound 5, with a unique aminoalkynyl group, was used as a chemical probe for exploring the mechanism of action (e.g., cellular uptake) of cycleanine in cancer cells using click chemistry (<xref rid="B15" ref-type="bibr">15</xref>), and can also be utilized for identification of the molecular target of cycleanine in parasite-infected blood cells using a chemoproteomic approach (<xref rid="B23" ref-type="bibr">23</xref>). By changing the amino substitution groups, additional analogues of cycleanine with a variety of diverse structures can be synthesized for <italic>in vitro</italic> antiplasmodial evaluation.</p><p>To further confirm and validate the efficacy of cycleanine (compound 1) <italic>in vivo</italic>, its safety in healthy mice and efficacy in a murine malaria model was investigated. The LD<sub>50</sub> (4.5 g/kg) of cycleanine indicated that cycleanine has a good safety profile, in agreement with the LD<sub>50</sub> of 1.1 g/kg found previously in mice (<xref rid="B24" ref-type="bibr">24</xref>). Using suppression, prophylactic, and curative murine malaria models after infection with <named-content content-type="genus-species">P. berghei</named-content> (<xref rid="B25" ref-type="bibr">25</xref>), cycleanine showed a similar or closer effect at an oral dose of 50&#x02009;mg/kg to their positive controls (chloroquine [5&#x02009;mg/kg] and pyrimethamine [1.2&#x02009;mg/kg]). At least, a much higher dose of cycleanine was needed to achieve the effects of these positive controls, indicating a mild efficacy <italic>in vivo</italic>. However, its low toxicity profile could allow increase of the oral dose (e.g., 100&#x02009;mg/kg/day), which is expected to improve its efficacy. In the curative model, the slower effect of cycleanine comparing to chloroquine might be due to the metabolism of cycleanine to various metabolites. The <italic>in vivo</italic> antimalarial activity of cycleanine was consistent with its <italic>in vitro</italic> antiplasmodial activity. To our knowledge, this is the first demonstration of the <italic>in vivo</italic> antimalarial efficacy of a BBIQ alkaloid, cycleanine. Overall, three alkaloids (compounds <xref rid="B1" ref-type="bibr">1</xref> to <xref rid="B3" ref-type="bibr">3</xref>) of <italic>T. subcordata</italic> could contribute to the antimalarial effects of this medicinal plant used in Nigeria for the treatment of malaria. BBIQ alkaloids of <named-content content-type="genus-species">Triclisia gilletii</named-content> (De Wild) Staner were also reported to be attributed to the <italic>in vitro</italic> and <italic>in vivo</italic> antimalarial activity of its plant extract (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>Study on the metabolism of drugs can help to further understand their pharmacokinetics, efficacy, and safety (<xref rid="B27" ref-type="bibr">27</xref>). For example, metabolites of piperaquine were shown to have stronger antiplasmodial activity (<xref rid="B28" ref-type="bibr">28</xref>). However, there have been only a few <italic>in vivo</italic> metabolism studies of BBIQ alkaloids. Previously, <italic>in vitro</italic> metabolites of a BBIQ alkaloid, isoliensinine, from dog hepatic microsomes were identified as 2&#x02032;-<italic>N</italic>-desmethylisoliensinine, 2-<italic>N</italic>-desmethyl-isoliensinine, and 2&#x02032;-<italic>N</italic>-6-<italic>O</italic>-didesmethylisoliensinine (<xref rid="B29" ref-type="bibr">29</xref>). The study of the pharmacokinetics and metabolism of another BBIQ alkaloid, neferine, indicated that it was partially converted to liensinine, desmethyl-liensinine, isoliensinine, and desmethyl-isoliensinine by CYP2D6 (<xref rid="B30" ref-type="bibr">30</xref>). Tetrandrine was found to be initially biotransformed to a quinone methide-derived metabolite mediated by CYP3A enzymes, which was then trapped by a glutathione molecule to form a glutathione conjugate in mice (<xref rid="B31" ref-type="bibr">31</xref>). Metabolism of isotetrandrine <italic>in vitro</italic> by the rat hepatic system produced a major metabolite, <italic>N</italic>-desmethyl isotetrandrine (16%), and three minor oxidized metabolites, oxo-isotetrandrine (7%), hydroxy-isotetrandrine (6%), and oxohydroxy-isotetrandrine (7%), via <italic>N</italic>-demethylation and isoquinoline ring oxidation (<xref rid="B32" ref-type="bibr">32</xref>).</p><p>Our identification of 12 new metabolites of cycleanine in both plasma and urine in rats using LC-MS/MS has indicated that there are various metabolic pathways of cycleanine. These metabolites of cycleanine found in rats are also likely generated in mice after the same route of oral administration, and therefore they could contribute to its <italic>in vivo</italic> antimalarial efficacy found in the murine malarial model and its toxicity finding in healthy mice. Hydroxylation and demethylation of cycleanine were the common pathways consistent with those found in isoliensinine, neferine, and isotetrandrine described above. Preparation of these metabolites through chemical synthesis (<xref rid="B33" ref-type="bibr">33</xref>) or <italic>in vitro</italic> biotransformation using hepatic microsomes and/or P450 enzymes (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>) is possible and necessary to evaluate their potency and toxicity. Such information can be used to further guide the chemical design and modification of cycleanine to improve its potency and pharmacokinetics and to increase metabolic stability (<xref rid="B36" ref-type="bibr">36</xref>). Further work is necessary and ongoing in our laboratory to determine the <italic>in vivo</italic> antimalarial effects of BBIQ alkaloids (compounds 2 and 3) and semisynthetic derivatives (compounds 4 and 5) and the <italic>in vitro</italic> and/or <italic>in vivo</italic> antimalarial activity of the metabolites of cycleanine. Novel active drugs, particularly those with a wide safety margin, are required to help alleviate malaria morbidity and mortality and to contribute to the global control of malaria and infectious diseases.</p></sec><sec sec-type="materials|methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4.1"><title>Chemicals.</title><p>Chloroquine and pyrimethamine were sourced from Sigma-Aldrich. Cycleanine (compound 1) (<xref rid="B13" ref-type="bibr">13</xref>), and two minor alkaloids, isochondodendrine (compound 2) and 2&#x02032;-norcocsuline (compound 3), were isolated from <italic>Triclisia subcordata</italic> (<xref rid="B14" ref-type="bibr">14</xref>). Compounds 4 and 5 (<xref ref-type="fig" rid="F1">Fig. 1</xref>) were previously prepared from cycleanine (compound 1) (<xref rid="B15" ref-type="bibr">15</xref>).</p></sec><sec id="s4.2"><title><italic>In vitro</italic> antiplasmodial activity.</title><p>The evaluation of <italic>in vitro</italic> antiplasmodial activity of the alkaloids (compounds 1 to 3) and semisynthetic analogues (compounds 4 and 5) were performed on the intraerythrocytic <named-content content-type="genus-species">P. falciparum</named-content> Dd2 strain (chloroquine-resistant strain) using a SYBR green1 fluorescence dye assay as described (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Compounds 1 to 5 were prepared in dimethyl sulfoxide (DMSO) with no greater than 1% of the total solvent concentration in any assay. Normalized fluorescence signals were measured against controls with 1% DMSO (100% growth) and after exposure to a supralethal concentration (10&#x02009;&#x003bc;M) of chloroquine (0% growth). Determination of the 50% inhibitory concentration (IC<sub>50</sub>) was performed from a log concentration versus the mean normalized fluorescence signal curve using GraphPad Prism software (v5.0). Each biological replicate consisted of three technical repeats, with three independent biological replicates performed.</p></sec><sec id="s4.3"><title>Evaluation of the <italic>in vivo</italic> antimalarial activity of cycleanine.</title><p><bold>(i) Malaria parasite.</bold> Chloroquine-sensitive strains of <named-content content-type="genus-species">P. berghei</named-content> were sourced from the National Institute of Medical Research (NIMER), Yaba Lagos, Nigeria, and maintained by subpassage in mice.</p><p><bold>(ii) Parasite inoculation.</bold> Each mouse was inoculated intraperitoneally with about 1&#x02009;&#x000d7;&#x02009;10<sup>7</sup>
<named-content content-type="genus-species">P. berghei</named-content> parasitized erythrocytes in 0.2&#x02009;ml of infected blood (5&#x02009;&#x000d7;&#x02009;10<sup>7</sup>
<named-content content-type="genus-species">P. berghei</named-content> erythrocytes/ml) according to published procedure (<xref rid="B39" ref-type="bibr">39</xref>).</p><p><bold>(iii) Experimental animals.</bold> Female and male Swiss albino mice (18 to 25 g) were obtained from the University of Uyo&#x02019;s animal house. Before use, mice were kept in cages and acclimatized for 10&#x02009;days. All mice were kept in cross-ventilated rooms at room temperature. The care and use of mice were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (1996). This investigation was approved by the University of Uyo&#x02019;s Animal Ethics Committee.</p><p><bold>(iv) Determination of median lethal dose (LD<sub>50</sub>) of cycleanine.</bold> The median lethal dose (LD<sub>50</sub>) of cycleanine was determined using albino mice by the intraperitoneal (i.p.) route (<xref rid="B40" ref-type="bibr">40</xref>). Different doses of cycleanine (10 to 5,000&#x02009;mg/kg) were intraperitoneally administered to groups of three mice each. The mice were monitored for manifestation of physical signs of toxicity, including decrease of motor activity, writhing, decrease of body/limb tone, weakness, and death. The number of deaths in each group within 24 h was recorded. The LD<sub>50</sub> value was calculated as the geometrical means of the minimum dose producing 100% mortality and the maximum dose producing 0%.</p><p><bold>(v) Drug administration.</bold> Cycleanine, chloroquine, and pyrimethamine were prepared in water and administered orally with the aid of a stainless metallic feeding cannula.</p><p><bold>(vi) Suppressive activity of cycleanine.</bold> The schizontocidal activity of cycleanine and chloroquine against early <named-content content-type="genus-species">P. berghei</named-content> infection in mice was measured according to an established protocol (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). On the first day, 20 to 24 mice were infected with the parasite and randomly separated into four groups. The mice in groups 1 and 2 were given 25 and 50&#x02009;mg/kg of cycleanine, respectively, those in group 3 were given 5&#x02009;mg/kg of chloroquine (positive control), and those in group 4 were given distilled water (10&#x02009;ml/kg, negative control) for four consecutive days. Thin films were made from the tail blood on the fifth day. Parasitized erythrocytes were counted in stained films (Giemsa stain) under a microscope. The average suppression of parasitemia (%) was calculated as follows: 
<disp-formula id="uFD1"><alternatives><graphic xlink:href="AAC.01995-20-m0001.jpg" position="float" orientation="portrait"/><mml:math id="um1"><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>average % parasitemia positive control</mml:mtext><mml:mi mathvariant="normal">&#x02212;</mml:mi><mml:mtext>average % parasitemia negative control</mml:mtext></mml:mrow><mml:mrow><mml:mtext>average % parasitemia negative control</mml:mtext></mml:mrow></mml:mfrac><mml:mi mathvariant="normal">&#x000d7;</mml:mi><mml:mn>100</mml:mn></mml:mrow></mml:math></alternatives></disp-formula></p><p>The MST (in days) of the mice in each group was determined over a period of 30&#x02009;days.</p><p><bold>(vii) Prophylactic activity of cycleanine.</bold> The prophylactic activity of cycleanine was evaluated using a previously described method (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). The mice were randomly divided into four groups of six mice per group. Groups 1 and 2 were given 25 and 50&#x02009;mg/kg of cycleanine, respectively, group 3 was given 1.2&#x02009;mg/kg of pyrimethamine (positive control), and group 4 was given 10&#x02009;ml/kg of distilled water (negative control). Administration of cycleanine or the drug continued for three consecutive days. On the fourth day, the mice were inoculated with <named-content content-type="genus-species">P. berghei</named-content>. The parasitemia level was evaluated by blood smears after 3&#x02009;days. The survival times (days) of the mice were recorded over a period of 30&#x02009;days, and MST were calculated.</p><p><bold>(viii) Curative activity of cycleanine.</bold> The curative activity of cycleanine was assessed according to a method described previously (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B44" ref-type="bibr">44</xref>). <named-content content-type="genus-species">P. berghei</named-content> was injected intraperitoneally into another 24 mice on the first day. Three days later, the mice were also separated into four groups of six mice per group. Groups 1 and 2 were administered different doses of cycleanine, 25 and 50&#x02009;mg/kg, respectively, group 3 was given 5&#x02009;mg/kg chloroquine (positive control), and group 4 was given 10&#x02009;ml/kg distilled water (negative control). Cycleanine and chloroquine were given once a day for 5&#x02009;days. Mouse tail blood samples were collected on each day, and Giemsa-stained thin smears were prepared to determine the parasitemia level. The MST of the mice in each group was determined over a period of 30&#x02009;days.</p></sec><sec id="s4.4"><title>Metabolism of cycleanine in rats.</title><p><bold>(i) High-performance liquid chromatography&#x02013;quadrupole time-of-flight tandem mass spectrometry.</bold> Analysis of cycleanine metabolites was performed through high-performance liquid chromatography&#x02013;quadrupole time-of-flight tandem mass spectrometry (HPLC-QTOF-MS/MS) system that consists of an Agilent 1260 HPLC coupled with an 6530 QTOF mass spectrometer with dual Agilent Jet Stream electrospray ionization source (Agilent Technologies, CA). The mass spectra were recorded in positive auto MS/MS mode, and the parameters were set as follows: temperature of drying and sheath gas, 300&#x000b0;C and 350&#x000b0;C; skimmer, 75 V; capillary voltage, 4,000 V; fragmentor, 110 V; nozzle voltage, 1,000 V; collision energy, 50&#x02009;eV; pressure of nebulizer, 35 lb/in<sup>2</sup>; and flow rate of the drying and sheath gas, 5 and 11 liter/min, respectively. The QTOF mass spectra were recorded in high-resolution mode. The range of mass-to-charge ratio (<italic>m/z</italic>) scanning was set between 100 and 1,200. Samples (5 &#x003bc;l) were loaded onto an Agilent Poroshell 120 EC-C<sub>18</sub> column (100&#x02009;&#x000d7;&#x02009;2.1&#x02009;mm, 2.7&#x02009;&#x003bc;m) at 35&#x000b0;C. The mobile phase consisted of water containing 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B) at a flow rate of 0.35&#x02009;ml/min. Gradient separation was achieved by changing the proportion of the solvent B mobile phase as follows: 0 to 2&#x02009;min, 10% B; 2.1 to 5&#x02009;min, 18% to 20% B; 30 to 45&#x02009;min, 70% to 90% B; and 45 to 50&#x02009;min, 10% B. MassHunter WorkStation software (Agilent Technologies) was utilized for the system operation and data analysis.</p><p><bold>(ii) <italic>In vivo</italic> experiments.</bold>
<italic>In vivo</italic> animal experiments were approved by the Animal Ethics Committee of Shanghai Institute of Materia Medica, and performed according to procedures approved by the Institutional Animal Care and Use Committee of Shanghai Institute of Materia Medica, Chinese Academy of Science. Male Wistar rats were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). The rats were given free access to water and a standard diet under controlled humidity (45% to 55%) and temperature (20&#x000b0;C to 24&#x000b0;C), except in the overnight fasting period before administration of cycleanine. The rats were adapted to the environment for a week.</p><p>Cycleanine (compound 1) was suspended in 0.4% carboxymethyl cellulose sodium (CMC-Na) and was formulated at 12&#x02009;mg/ml for intragastric administration to Wistar rats (male, 220&#x02009;&#x000b1;&#x02009;10 g, fasted for 12&#x02009;h prior to administration) at a dose of 120&#x02009;mg/kg body weight. Three rats were used for blood collection through the orbital vein using cannulation at 0, 0.5, 1, 2, 4, 6, 8, 12, and 24 h postdose after anaesthetization with isoflurane. The plasma samples were separated from blood by centrifugation at 12,000&#x02009;rpm and 4&#x000b0;C for 10&#x02009;min. Another three rats were placed in the metabolism cages, and urine samples were collected into tubes from 0 to 24 h after oral administration of cycleanine. All samples were stored in a &#x02212;80&#x000b0;C freezer before analysis. Aliquots of 1.2&#x02009;ml of plasma or urine samples were mixed with 3 times the volume of acetonitrile to precipitate proteins. After centrifugation at 14,000&#x02009;rpm for 10&#x02009;min, the supernatant was collected and evaporated under vacuum. The residue was reconstituted in 200 &#x003bc;l methanol, and 5 &#x003bc;l of each sample was injected for HPLC-QTOF-MS/MS analysis.</p></sec><sec id="s4.5"><title>Statistical analysis.</title><p>Data were expressed as mean &#x000b1; standard error of the mean (SEM) for <italic>in vivo</italic> antimalarial experiments. Data were subjected to GraphPad Prism software analysis. Results were analyzed using one-way analysis of variance (ANOVA) followed by a <italic>post hoc</italic> Tukey multiple-comparison test. The difference between the mean of the experimental and control groups was considered significant at a <italic>P</italic> value of &#x0003c;0.05 (ANOVA).</p></sec><sec id="s4.6" sec-type="conclusions"><title>Conclusions.</title><p>Three BBIQ alkaloids of <italic>T. subcordata</italic>, cycleanine (compound 1), isochondodendrine (compound 2), and 2&#x02032;-norcocsuline (compound 3) and two semisynthetic analogues (compounds 4 and 5) of cycleanine were demonstrated to exert significant <italic>in vitro</italic> antiplasmodial activities against <named-content content-type="genus-species">P. falciparum</named-content>. Cycleanine (compound 1) was further demonstrated to have safety and efficacy in the treatment of mice infected with <named-content content-type="genus-species">P. berghei</named-content>. Cycleanine was transformed to various metabolites in rats after oral delivery. The findings from this study support the use of <italic>T. subcordata</italic> as an antimalarial agent in traditional medicine. BBIQ alkaloids could be exploited in novel drug development in search of antimalarial agents/drugs that are urgently needed to challenge resistant plasmodium species that currently present a significant threat to human life.</p></sec></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplemental file 1</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="AAC.01995-20-s0001.pdf"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="supplementary-material"><p>Supplemental material is available online only.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>This research was funded by Nigerian ETF and NDDC and by BBSRC (HVfCP business interaction voucher).</p><p>We declare no conflict of interest.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><mixed-citation publication-type="book"><collab>WHO</collab>. <year>2019</year>
<source>World malaria report 2019</source>. <publisher-name>World Health Organization</publisher-name>, <publisher-loc>Geneva, Switzerland</publisher-loc>
<ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/rest/bitstreams/1262394/retrieve">https://apps.who.int/iris/rest/bitstreams/1262394/retrieve</ext-link>.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bhatt</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Weiss</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Cameron</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Bisanzio</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Mappin</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Dalrymple</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Battle</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Moyes</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Henry</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Eckhoff</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Wenger</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Briet</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Penny</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Bennett</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yukich</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Eisele</surname>
<given-names>TP</given-names></string-name>, <string-name><surname>Griffin</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Fergus</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Lynch</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lindgren</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Cohen</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Murray</surname>
<given-names>CLJ</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Hay</surname>
<given-names>SI</given-names></string-name>, <string-name><surname>Cibulskis</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Gething</surname>
<given-names>PW</given-names></string-name></person-group>
<year>2015</year>
<article-title>The effect of malaria control on <italic>Plasmodium falciparum</italic> in Africa between 2000 and 2015</article-title>. <source>Nature</source>
<volume>526</volume>:<fpage>207</fpage>&#x02013;<lpage>211</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature15535</pub-id>.<pub-id pub-id-type="pmid">26375008</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spring</surname>
<given-names>MD</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Manning</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Vanachayangkul</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Somethy</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bun</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Se</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chann</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ittiverakul</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sia-Ngam</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kuntawunginn</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Arsanok</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Buathong</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Chaorattanakawee</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gosi</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ta-Aksorn</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Chanarat</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Sundrakes</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kong</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Heng</surname>
<given-names>TK</given-names></string-name>, <string-name><surname>Nou</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Teja-Isavadharm</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Pichyangkul</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Phann</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Balasubramanian</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Juliano</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Meshnick</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Chour</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Prom</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lanteri</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Lon</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Saunders</surname>
<given-names>DL</given-names></string-name></person-group>
<year>2015</year>
<article-title>Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study</article-title>. <source>Lancet Infect Dis</source>
<volume>15</volume>:<fpage>683</fpage>&#x02013;<lpage>691</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(15)70049-6</pub-id>.<pub-id pub-id-type="pmid">25877962</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cragg</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Newman</surname>
<given-names>DJ</given-names></string-name></person-group>
<year>2013</year>
<article-title>Natural products: a continuing source of novel drug leads</article-title>. <source>Biochim Biophys Acta</source>
<volume>1830</volume>:<fpage>3670</fpage>&#x02013;<lpage>3695</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbagen.2013.02.008</pub-id>.<pub-id pub-id-type="pmid">23428572</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fernandez-Alvaro</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Hong</surname>
<given-names>WD</given-names></string-name>, <string-name><surname>Nixon</surname>
<given-names>GL</given-names></string-name>, <string-name><surname>O'Neill</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Calderon</surname>
<given-names>F</given-names></string-name></person-group>
<year>2016</year>
<article-title>Antimalarial chemotherapy: natural product inspired development of preclinical and clinical candidates with diverse mechanisms of action</article-title>. <source>J Med Chem</source>
<volume>59</volume>:<fpage>5587</fpage>&#x02013;<lpage>5603</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01485</pub-id>.<pub-id pub-id-type="pmid">26791529</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bridgford</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Cobbold</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Pasaje</surname>
<given-names>CFA</given-names></string-name>, <string-name><surname>Herrmann</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Gillett</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Dick</surname>
<given-names>LR</given-names></string-name>, <string-name><surname>Ralph</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Dogovski</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Spillman</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Tilley</surname>
<given-names>L</given-names></string-name></person-group>
<year>2018</year>
<article-title>Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome</article-title>. <source>Nat Commun</source>
<volume>9</volume>:<fpage>3801</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-018-06221-1</pub-id>.<pub-id pub-id-type="pmid">30228310</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tu</surname>
<given-names>Y</given-names></string-name></person-group>
<year>2016</year>
<article-title>Artemisinin&#x02014;a gift from traditional Chinese medicine to the world (Nobel Lecture)</article-title>. <source>Angew Chem Int Ed Engl</source>
<volume>55</volume>:<fpage>10210</fpage>&#x02013;<lpage>10226</lpage>. doi:<pub-id pub-id-type="doi">10.1002/anie.201601967</pub-id>.<pub-id pub-id-type="pmid">27488942</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Culleton</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ramaprasad</surname>
<given-names>A</given-names></string-name>, <string-name><surname>von Seidlein</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Menard</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Pain</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>J</given-names></string-name></person-group>
<year>2017</year>
<article-title>Emergence of indigenous artemisinin-resistant <italic>Plasmodium falciparum</italic> in Africa</article-title>. <source>N Engl J Med</source>
<volume>376</volume>:<fpage>991</fpage>&#x02013;<lpage>993</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMc1612765</pub-id>.<pub-id pub-id-type="pmid">28225668</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schiff</surname>
<given-names>PL</given-names></string-name></person-group>
<year>1997</year>
<article-title>Bisbenzylisoquinoline alkaloids</article-title>. <source>J Nat Prod</source>
<volume>60</volume>:<fpage>934</fpage>&#x02013;<lpage>953</lpage>. doi:<pub-id pub-id-type="doi">10.1021/np9700174</pub-id>.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weber</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Opatz</surname>
<given-names>T</given-names></string-name></person-group>
<year>2019</year>
<article-title>Bisbenzylisoquinoline alkaloids</article-title>. <source>Alkaloids Chem Biol</source>
<volume>81</volume>:<fpage>1</fpage>&#x02013;<lpage>114</lpage>. doi:<pub-id pub-id-type="doi">10.1016/bs.alkal.2018.07.001</pub-id>.<pub-id pub-id-type="pmid">30685048</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Sofowora</surname>
<given-names>LA</given-names></string-name></person-group>
<year>1982</year>
<source>Medicinal plants and traditional medicine in Africa</source>. <publisher-name>John Wiley and Sons Limited</publisher-name>, <publisher-loc>Chichester, United Kingdom</publisher-loc>.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Asuzu</surname>
<given-names>IU</given-names></string-name>, <string-name><surname>Anaga</surname>
<given-names>AO</given-names></string-name></person-group>
<year>1996</year>
<article-title>The antiulcer effect of the methanolic extract of <italic>Triclisia subcordata</italic> leaves in rats</article-title>. <source>J Herbs Spices Med Plants</source>
<volume>3</volume>:<fpage>45</fpage>&#x02013;<lpage>53</lpage>. doi:<pub-id pub-id-type="doi">10.1300/J044v03n03_07</pub-id>.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uche</surname>
<given-names>FI</given-names></string-name>, <string-name><surname>Drijfhout</surname>
<given-names>FP</given-names></string-name>, <string-name><surname>McCullagh</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Richardson</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>WW</given-names></string-name></person-group>
<year>2016</year>
<article-title>Cytotoxicity effects and apoptosis induction by bisbenzylisoquinoline alkaloids from <italic>Triclisia subcordata</italic></article-title>. <source>Phytother Res</source>
<volume>30</volume>:<fpage>1533</fpage>&#x02013;<lpage>1539</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ptr.5660</pub-id>.<pub-id pub-id-type="pmid">27270992</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uche</surname>
<given-names>FI</given-names></string-name>, <string-name><surname>Abed</surname>
<given-names>MN</given-names></string-name>, <string-name><surname>Abdullah</surname>
<given-names>MI</given-names></string-name>, <string-name><surname>Drijfhout</surname>
<given-names>FP</given-names></string-name>, <string-name><surname>McCullagh</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Claridge</surname>
<given-names>TWD</given-names></string-name>, <string-name><surname>Richardson</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>WW</given-names></string-name></person-group>
<year>2017</year>
<article-title>Isochondodendrine and 2&#x02032;-norcocsuline: additional alkaloids from <italic>Triclisia subcordata</italic>, induced cytotoxicity and apoptosis in ovarian cancer cell lines</article-title>. <source>RSC Adv</source>
<volume>7</volume>:<fpage>44154</fpage>&#x02013;<lpage>44161</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C7RA08032H</pub-id>.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uche</surname>
<given-names>FI</given-names></string-name>, <string-name><surname>McCullagh</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Claridge</surname>
<given-names>TWD</given-names></string-name>, <string-name><surname>Richardson</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>WW</given-names></string-name></person-group>
<year>2018</year>
<article-title>Synthesis of (aminoalkyl)cycleanine analogues: cytotoxicity, cellular uptake, and apoptosis induction in ovarian cancer cells</article-title>. <source>Bioorg Med Chem Lett</source>
<volume>28</volume>:<fpage>1652</fpage>&#x02013;<lpage>1656</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmcl.2018.03.038</pub-id>.<pub-id pub-id-type="pmid">29588214</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angerhofer</surname>
<given-names>CK</given-names></string-name>, <string-name><surname>Guinaudeau</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wongpanich</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Pezzuto</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Cordell</surname>
<given-names>GA</given-names></string-name></person-group>
<year>1999</year>
<article-title>Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids</article-title>. <source>J Nat Prod</source>
<volume>62</volume>:<fpage>59</fpage>&#x02013;<lpage>66</lpage>. doi:<pub-id pub-id-type="doi">10.1021/np980144f</pub-id>.<pub-id pub-id-type="pmid">9917283</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fadaeinasab</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Taha</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Fauzi</surname>
<given-names>PN</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Widyawaruyanti</surname>
<given-names>A</given-names></string-name></person-group>
<year>2015</year>
<article-title>Anti-malarial activity of isoquinoline alkaloids from the stem bark of <italic>Actinodaphne macrophylla</italic></article-title>. <source>Nat Prod Commun</source>
<volume>10</volume>:<fpage>1541</fpage>&#x02013;<lpage>1542</lpage>.<pub-id pub-id-type="pmid">26594753</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Otshudi</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Apers</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pieters</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Claeys</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pannecouque</surname>
<given-names>C</given-names></string-name>, <string-name><surname>De Clercq</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Van Zeebroeck</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lauwers</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Frederich</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Foriers</surname>
<given-names>A</given-names></string-name></person-group>
<year>2005</year>
<article-title>Biologically active bisbenzylisoquinoline alkaloids from the root bark of <italic>Epinetrum villosum</italic></article-title>. <source>J Ethnopharmacol</source>
<volume>102</volume>:<fpage>89</fpage>&#x02013;<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jep.2005.05.021</pub-id>.<pub-id pub-id-type="pmid">15996841</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mambu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Martin</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Razafimahefa</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ramanitrahasimbola</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Rasoanaivo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Frappier</surname>
<given-names>F</given-names></string-name></person-group>
<year>2000</year>
<article-title>Spectral characterisation and antiplasmodial activity of bisbenzylisoquinolines from <italic>Isolona ghesquiereina</italic></article-title>. <source>Planta Med</source>
<volume>66</volume>:<fpage>537</fpage>&#x02013;<lpage>540</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-2000-8610</pub-id>.<pub-id pub-id-type="pmid">10985080</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guinaudeau</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Bohlke</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>LZ</given-names></string-name>, <string-name><surname>Angerhofer</surname>
<given-names>CK</given-names></string-name>, <string-name><surname>Cordell</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Ruangrungsi</surname>
<given-names>N</given-names></string-name></person-group>
<year>1997</year>
<article-title>(+)-Angchibangkine, a new type of bisbenzylisoquinoline alkaloid, and other dimers from <italic>Pachygone dasycarpa</italic></article-title>. <source>J Nat Prod</source>
<volume>60</volume>:<fpage>258</fpage>&#x02013;<lpage>260</lpage>. doi:<pub-id pub-id-type="doi">10.1021/np960568e</pub-id>.<pub-id pub-id-type="pmid">9157192</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kingsbury</surname>
<given-names>WD</given-names></string-name>, <string-name><surname>Boehm</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Jakas</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Holden</surname>
<given-names>KG</given-names></string-name>, <string-name><surname>Hecht</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Gallagher</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Caranfa</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>McCabe</surname>
<given-names>FL</given-names></string-name>, <string-name><surname>Faucette</surname>
<given-names>LF</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>RK</given-names></string-name></person-group>
<year>1991</year>
<article-title>Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity</article-title>. <source>J Med Chem</source>
<volume>34</volume>:<fpage>98</fpage>&#x02013;<lpage>107</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jm00105a017</pub-id>.<pub-id pub-id-type="pmid">1846923</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson-Ajinwo</surname>
<given-names>OR</given-names></string-name>, <string-name><surname>Ullah</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Mbye</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Richardson</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Horrocks</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>WW</given-names></string-name></person-group>
<year>2018</year>
<article-title>The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents</article-title>. <source>Bioorg Med Chem Lett</source>
<volume>28</volume>:<fpage>1219</fpage>&#x02013;<lpage>1222</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmcl.2018.02.051</pub-id>.<pub-id pub-id-type="pmid">29519737</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Drewes</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Knapp</surname>
<given-names>S</given-names></string-name></person-group>
<year>2018</year>
<article-title>Chemoproteomics and chemical probes for target discovery</article-title>. <source>Trends Biotechnol</source>
<volume>36</volume>:<fpage>1275</fpage>&#x02013;<lpage>1286</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tibtech.2018.06.008</pub-id>.<pub-id pub-id-type="pmid">30017093</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wambebe</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gamaniel</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Akah</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kapu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Samson</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Orisadipe</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Okogun</surname>
<given-names>J</given-names></string-name></person-group>
<year>1997</year>
<article-title>Central and uterotonic effects of cycleanine</article-title>. <source>Indian J Pharmcol</source>
<volume>29</volume>:<fpage>366</fpage>&#x02013;<lpage>372</lpage>.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fidock</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Rosenthal</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Croft</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Brun</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Nwaka</surname>
<given-names>S</given-names></string-name></person-group>
<year>2004</year>
<article-title>Antimalarial drug discovery: efficacy models for compound screening</article-title>. <source>Nat Rev Drug Discov</source>
<volume>3</volume>:<fpage>509</fpage>&#x02013;<lpage>520</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrd1416</pub-id>.<pub-id pub-id-type="pmid">15173840</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kikueta</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Kambu</surname>
<given-names>OK</given-names></string-name>, <string-name><surname>Mbenza</surname>
<given-names>AP</given-names></string-name>, <string-name><surname>Mavinga</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Mbamu</surname>
<given-names>BM</given-names></string-name>, <string-name><surname>Cos</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Maes</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Apers</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pieters</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cimanga</surname>
<given-names>RK</given-names></string-name></person-group>
<year>2013</year>
<article-title><italic>In vitro</italic> and <italic>in vivo</italic> antimalarial activity and cytotoxicity of extracts and fractions from the leaves, root-bark and stem-bark of <italic>Triclisia gilletii</italic></article-title>. <source>J Ethnopharmacol</source>
<volume>149</volume>:<fpage>438</fpage>&#x02013;<lpage>442</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jep.2013.06.043</pub-id>.<pub-id pub-id-type="pmid">23876596</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yisimayili</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Abdulla</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Akber Aisa</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>C</given-names></string-name></person-group>
<year>2019</year>
<article-title>Metabolic profiling analysis of corilagin <italic>in vivo</italic> and <italic>in vitro</italic> using high-performance liquid chromatography quadrupole time-of-flight mass spectrometry</article-title>. <source>J Pharm Biomed Anal</source>
<volume>165</volume>:<fpage>251</fpage>&#x02013;<lpage>260</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpba.2018.12.013</pub-id>.<pub-id pub-id-type="pmid">30562708</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Cai</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Zang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Xing</surname>
<given-names>J</given-names></string-name></person-group>
<year>2018</year>
<article-title>Metabolism of piperaquine to its antiplasmodial metabolites and their pharmacokinetic profiles in healthy volunteers</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>62</volume>:<comment>e00260-18</comment>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00260-18</pub-id>.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zeng</surname>
<given-names>S</given-names></string-name></person-group>
<year>2012</year>
<article-title>Identification of three new <italic>N</italic>-demethylated and <italic>O</italic>-demethylated bisbenzylisoquinoline alkaloid metabolites of isoliensinine from dog hepatic microsomes</article-title>. <source>Molecules</source>
<volume>17</volume>:<fpage>11712</fpage>&#x02013;<lpage>11720</lpage>. doi:<pub-id pub-id-type="doi">10.3390/molecules171011712</pub-id>.<pub-id pub-id-type="pmid">23027371</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Bai</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Xiang</surname>
<given-names>J</given-names></string-name></person-group>
<year>2007</year>
<article-title>Pharmacokinetics and metabolism of neferine in rats after a single oral administration</article-title>. <source>Biopharm Drug Dispos</source>
<volume>28</volume>:<fpage>361</fpage>&#x02013;<lpage>372</lpage>. doi:<pub-id pub-id-type="doi">10.1002/bdd.556</pub-id>.<pub-id pub-id-type="pmid">17654697</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Zeng</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>J</given-names></string-name></person-group>
<year>2016</year>
<article-title>CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine</article-title>. <source>Arch Toxicol</source>
<volume>90</volume>:<fpage>1737</fpage>&#x02013;<lpage>1748</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00204-015-1584-8</pub-id>.<pub-id pub-id-type="pmid">26302866</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname>
<given-names>WN</given-names></string-name>, <string-name><surname>McKown</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Gopaul</surname>
<given-names>VS</given-names></string-name></person-group>
<year>2004</year>
<article-title><italic>In-vitro</italic> metabolism of isotetrandrine, a bisbenzylisoquinoline alkaloid, in rat hepatic S9 fraction by high-performance liquid chromatography-atmospheric pressure ionization mass spectrometry</article-title>. <source>J Pharm Pharmacol</source>
<volume>56</volume>:<fpage>749</fpage>&#x02013;<lpage>755</lpage>. doi:<pub-id pub-id-type="doi">10.1211/0022357023547</pub-id>.<pub-id pub-id-type="pmid">15231040</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cernak</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Dykstra</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Tyagarajan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Vachal</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Krska</surname>
<given-names>SW</given-names></string-name></person-group>
<year>2016</year>
<article-title>The medicinal chemist's toolbox for late stage functionalization of drug-like molecules</article-title>. <source>Chem Soc Rev</source>
<volume>45</volume>:<fpage>546</fpage>&#x02013;<lpage>576</lpage>. doi:<pub-id pub-id-type="doi">10.1039/c5cs00628g</pub-id>.<pub-id pub-id-type="pmid">26507237</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ren</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Yorke</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Taylor</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>LL</given-names></string-name></person-group>
<year>2015</year>
<article-title>Drug oxidation by cytochrome P450BM3: metabolite synthesis and discovering new P450 reaction types</article-title>. <source>Chemistry</source>
<volume>21</volume>:<fpage>15039</fpage>&#x02013;<lpage>15047</lpage>. doi:<pub-id pub-id-type="doi">10.1002/chem.201502020</pub-id>.<pub-id pub-id-type="pmid">26311271</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cusack</surname>
<given-names>KP</given-names></string-name>, <string-name><surname>Koolman</surname>
<given-names>HF</given-names></string-name>, <string-name><surname>Lange</surname>
<given-names>UE</given-names></string-name>, <string-name><surname>Peltier</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Piel</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Vasudevan</surname>
<given-names>A</given-names></string-name></person-group>
<year>2013</year>
<article-title>Emerging technologies for metabolite generation and structural diversification</article-title>. <source>Bioorg Med Chem Lett</source>
<volume>23</volume>:<fpage>5471</fpage>&#x02013;<lpage>5483</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmcl.2013.08.003</pub-id>.<pub-id pub-id-type="pmid">23992859</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thompson</surname>
<given-names>TN</given-names></string-name></person-group>
<year>2001</year>
<article-title>Optimization of metabolic stability as a goal of modern drug design</article-title>. <source>Med Res Rev</source>
<volume>21</volume>:<fpage>412</fpage>&#x02013;<lpage>449</lpage>. doi:<pub-id pub-id-type="doi">10.1002/med.1017</pub-id>.<pub-id pub-id-type="pmid">11579441</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smilkstein</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sriwilaijaroen</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Kelly</surname>
<given-names>JX</given-names></string-name>, <string-name><surname>Wilairat</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Riscoe</surname>
<given-names>M</given-names></string-name></person-group>
<year>2004</year>
<article-title>Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>48</volume>:<fpage>1803</fpage>&#x02013;<lpage>1806</lpage>. doi:<pub-id pub-id-type="doi">10.1128/aac.48.5.1803-1806.2004</pub-id>.<pub-id pub-id-type="pmid">15105138</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aldulaimi</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Uche</surname>
<given-names>FI</given-names></string-name>, <string-name><surname>Hameed</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Mbye</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Ullah</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Drijfhout</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Claridge</surname>
<given-names>TDW</given-names></string-name>, <string-name><surname>Horrocks</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>WW</given-names></string-name></person-group>
<year>2017</year>
<article-title>A characterization of the antimalarial activity of the bark of <italic>Cylicodiscus gabunensis</italic> Harms</article-title>. <source>J Ethnopharmacol</source>
<volume>198</volume>:<fpage>221</fpage>&#x02013;<lpage>225</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jep.2017.01.014</pub-id>.<pub-id pub-id-type="pmid">28089716</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Odetola</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Basir</surname>
<given-names>O</given-names></string-name></person-group>
<year>1980</year>
<chapter-title>Evaluation of antimalarial properties of some Nigerian medicinal plants</chapter-title>, p <fpage>275</fpage>&#x02013;<lpage>283</lpage>. <italic>In</italic>
<person-group person-group-type="editor"><string-name><surname>Sofowora</surname>
<given-names>A</given-names></string-name></person-group> (ed), <source>Proceedings of African Bioscience Network, Federal Ministry of Science and Technology</source>. <comment>University of Ife Organized Workshop</comment>
<publisher-name>Nigerian Society of Pharmacology and Drug Research and Production Unit</publisher-name>, <publisher-loc>Ife, Nigeria</publisher-loc>.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lorke</surname>
<given-names>D</given-names></string-name></person-group>
<year>1983</year>
<article-title>A new approach to practical acute toxicity testing</article-title>. <source>Arch Toxicol</source>
<volume>54</volume>:<fpage>275</fpage>&#x02013;<lpage>287</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF01234480</pub-id>.<pub-id pub-id-type="pmid">6667118</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knight</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Peters</surname>
<given-names>W</given-names></string-name></person-group>
<year>1980</year>
<article-title>The antimalarial activity of <italic>N</italic>-benzyloxydihydrotriazines. I. The activity of clociguanil (BRL 50216) against rodent malaria, and studies on its mode of action</article-title>. <source>Ann Trop Med Parasitol</source>
<volume>74</volume>:<fpage>393</fpage>&#x02013;<lpage>404</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00034983.1980.11687360</pub-id>.<pub-id pub-id-type="pmid">7006531</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Okokon</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Antia</surname>
<given-names>BS</given-names></string-name>, <string-name><surname>Mohanakrishnan</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Sahal</surname>
<given-names>D</given-names></string-name></person-group>
<year>2017</year>
<article-title>Antimalarial and antiplasmodial activity of husk extract and fractions of <italic>Zea mays</italic></article-title>. <source>Pharm Biol</source>
<volume>55</volume>:<fpage>1394</fpage>&#x02013;<lpage>1400</lpage>. doi:<pub-id pub-id-type="doi">10.1080/13880209.2017.1302966</pub-id>.<pub-id pub-id-type="pmid">28320254</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peters</surname>
<given-names>W</given-names></string-name></person-group>
<year>1965</year>
<article-title>Drug resistance in <italic>Plasmodium berghei</italic> Vincke and Lips, 1948. I. Chloroquine resistance</article-title>. <source>Exp Parasitol</source>
<volume>17</volume>:<fpage>80</fpage>&#x02013;<lpage>89</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0014-4894(65)90012-3</pub-id>.<pub-id pub-id-type="pmid">5843289</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryley</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Peters</surname>
<given-names>W</given-names></string-name></person-group>
<year>1970</year>
<article-title>The antimalarial activity of some quinolone esters</article-title>. <source>Ann Trop Med Parasitol</source>
<volume>64</volume>:<fpage>209</fpage>&#x02013;<lpage>222</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00034983.1970.11686683</pub-id>.<pub-id pub-id-type="pmid">4992592</pub-id></mixed-citation></ref></ref-list></back></article>